BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29760791)

  • 1. Serum VEGF levels in the early diagnosis and severity assessment of non-small cell lung cancer.
    Lai Y; Wang X; Zeng T; Xing S; Dai S; Wang J; Chen S; Li X; Xie Y; Zhu Y; Liu W
    J Cancer; 2018; 9(9):1538-1547. PubMed ID: 29760791
    [No Abstract]   [Full Text] [Related]  

  • 2. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
    Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
    Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
    Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
    Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
    Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
    Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
    Chantapet P; Riantawan P; Lebnak P; Getngern P
    J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer.
    Sharma SK; Bhat S; Chandel V; Sharma M; Sharma P; Gupta S; Sharma S; Bhat AA
    J Carcinog; 2015; 14():7. PubMed ID: 26900349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Macrophage-colony stimulating factor (M-csf) in diagnostic and monitoring of non-small-cell lung cancer (NSCLC)].
    Mroczko B; Szmitkowski M
    Pol Arch Med Wewn; 2001 Mar; 105(3):203-9. PubMed ID: 11680264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
    Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V
    Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
    Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
    J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer anti-estrogen resistance protein 1 (BCAR1/p130cas) in pulmonary disease tissue and serum.
    Deng B; Huang W; Tan QY; Fan XQ; Jiang YG; Liu L; Zhong YY; Liang YG; Wang RW
    Mol Diagn Ther; 2011 Feb; 15(1):31-40. PubMed ID: 21469768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
    Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
    J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
    Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
    Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum lemur tyrosine kinase-3: a novel biomarker for screening primary non-small cell lung cancer and predicting cancer progression.
    Zhang K; Chen L; Deng H; Zou Y; Liu J; Shi H; Xu B; Lu M; Li C; Jiang J; Wang Z
    Int J Clin Exp Pathol; 2015; 8(1):629-35. PubMed ID: 25755755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low expression of miR-27b in serum exosomes of non-small cell lung cancer facilitates its progression by affecting EGFR.
    Cao X; Zhong W; Guo S; Zhang Z; Xie C
    Open Med (Wars); 2022; 17(1):816-825. PubMed ID: 35582197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Validation of Serum CST1 as a Diagnostic Marker for Differentiating Early-Stage Non-Small Cell Lung Cancer from Pulmonary Benign Nodules.
    Lai Y; Wang Y; Wu Y; Wu M; Xing S; Xie Y; Chen S; Li X; Zhang A; He Y; Li H; Dai S; Wang J; Lin S; Bai Y; Du H; Liu W
    Cancer Control; 2022; 29():10732748221104661. PubMed ID: 35653624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
    Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
    Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of circulating vascular endothelial growth factor and matrix metalloproteinase-9 in non-small cell lung cancer using Luminex multiplex technology.
    Zhang Y; Wu JZ; Zhang JY; Xue J; Ma R; Cao HX; Feng JF
    Oncol Lett; 2014 Feb; 7(2):499-506. PubMed ID: 24396477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
    Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
    Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.